Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258

•    A modified ProMisE algorithm was prognostic for recurrence free survival (RFS) and overall survival (OS).•    RFS seemed to be improved in patients with p53 wild type cancers who received chemoradiation in addition to chemotherapy.•    Patients who had tumors with abnormal p53 protein IHC had the worst RFS and OS compared to dMMR and p53 wild type cancers.

Fully automated extraction of high-quality total nucleic acids from FFPE specimens for comprehensive genomic profiling of solid tumors

Abstract: Comprehensive Genomic Profiling (CGP) has emerged as a progressive standard of care for the understandingclinical oncology and treatment of solid tumors (Conroy, Pabla et al. 2021). By identifying actionable mutationsthrough next-generation sequencing of solid tumors CGP enables targeted therapy decisions. Formalin-fixedparaffin-embedded tissues are notoriously difficult samples in respect to reliably extracting high-qualitynucleic acids and sufficient genetic material to meet sequencing input requirements. In this work we presentan automated solution for upstream sample processing of solid tumors to enable high throughput and scalableCGP workflows by eliminating bottlenecks and enhancing results. The Sonication STAR automated DNA and RNAmethods from FFPE Tissues was created as a collaboration between Hamilton Company, Covaris, and Labcorpand it offers the potential reduction in quantity not sufficient (QNS) samples and sequencing performance improvementsresulting in a 16 % increase in fully reported tumor profiles for patients. This automated approachoffers potential saving in workflow costs, improved efficiency, and a reduction in re-extraction and re-sequencingof tumors.

ESMO

Join Labcorp at ESMO on Oct 17 – Oct 21, 2025 | Berlin, Germany

Analytical Validation of the Labcorp® Plasma Complete™ Test, a Cell-Free DNA Comprehensive Genomic Profiling Tool for Precision Oncology

Key takeawaysThe Labcorp Plasma Complete test demonstrates high sensitivity, specificity, accuracy and robustnessThis liquid biopsy test enables tumor molecular profiling to inform treatment decisions

The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results, Practical Considerations for Personalized Cancer Care

For patients with advanced non-small cell lung cancer (NSCLC), tissue samples are typically small biopsies. These samples undergo standard of care evaluation for >10 biomarkers to identify targeted, personalized therapies. If only single-gene tests are ordered, it is unlikely all biomarkers will be successfully tested. Furthermore, the patient may not be able to get a second biopsy for comprehensive testing. Ordering single-gene tests before comprehensive profiling creates longer wait times for results, which can be problematic for selecting optimal treatment.

From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates

Labcorp Oncology's Medical Affairs Team explore the evolving role of HER2 overexpression in various solid tumors and discuss how advancements in Antibody Drug Conjugates, particularly T-DXd, are transforming treatment strategies in solid malignancies. They also highlight the challenges in HER2 testing across pan-solid tumors and the potential of NGS and AI algorithms to enhance diagnostic accuracy.

Graphical Summary: A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors

Key TakeawaysOur GIA calls aligned well with reference populations of inferred ancestries, were highly concordant with SIRE (95%), and could expand upon SIRE by detecting ancestries missing appropriate SIRE groups.Accurate GIA provides essential data to support ancestryaware biomarker research, promote the inclusion of underrepresented groups in clinical studies, and enhance diverse representation in precision clinical trials.